Developing novel pharmaceutical technology that provides for outstanding taste masking for a broad range of pharmaceuticals including major drug categories such as NSAIDS and statins.
The Company was notified on 11 March 2011 that, as at 4 March 2011, Mr David Richardson no longer has a notifiable interest in the Company's issued share capital.
For further information:
www.oxfordnutrascience.com
| Oxford Nutrascience Group Plc | |
| Nigel Theobald, Chief Executive | +44 1865 854874 |
| Mark Way, Investor and Media Relations | +44 7786 116991 |
ZAI Corporate Finance (Nominated Adviser) |
|
| John Depasquale | +44 20 7060 2220 |
| Sarang Shah | +44 20 7060 2220 |